DS
ELVN icon

David Shaw’s Enliven Therapeutics ELVN Stock Holding History

David Shaw’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.5M Buy
305,703
+112,172
+58% +$4.76M 0.01% 1477
2026
Q1 		$7.59M Buy
+193,531
New +$5.36M ﹤0.01% 1845
2022
Q1 		– Sell
-20,967
Closed -$189K – 5630
2021
Q4 		$189K Buy
20,967
+5,469
+35% +$71.7K ﹤0.01% 4900
2021
Q3 		$253K Buy
+15,498
New +$322K ﹤0.01% 4451

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

David Shaw's ELVN Position: Q2 2026 in Review

David Shaw increased its Enliven Therapeutics (ELVN) stake by 58% in Q2 2026, buying an estimated $4.76M and bringing the position to 305,703 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1477.

David Shaw first reported a position in ELVN in Q3 2021 and has held it in 4 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • David Shaw held 305,703 shares of Enliven Therapeutics worth $15.5M as of Q2 2026.
  • David Shaw bought 112,172 Enliven Therapeutics shares in Q2 2026, an estimated $4.76M.
  • Enliven Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1477 holding.
  • David Shaw first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.